ir.chiasmapharma.com: Investor Relations Home | Chiasma

Chiasma is a biopharmaceutical company dedicated to developing and commercializing peptide therapeutics that may open new indications and increase patient choice. The company’s proprietary, validated TPE® (Transient Permeability Enhancer) technology is the engine that powers its product pipeline. Chiasma targets drugs and indications with a clear clinical development and regulatory path and the opportunity for a significant competitive advantage. It focuses on orphan indications whenever possible.